In a 53-year-old man with normocytic anemia, mild thrombocytopenia, and mildly elevated transaminases, can these findings cause restless‑legs syndrome?

Yes, normocytic anemia and thrombocytopenia can cause restless legs syndrome, particularly through iron deficiency mechanisms.

In this 53-year-old man with normocytic anemia, mild thrombocytopenia, and elevated transaminases, the hematologic abnormalities can directly trigger RLS through iron deficiency, even if serum iron studies appear normal. The key is that RLS pathophysiology involves brain iron deficiency in specific regions, not just systemic iron depletion 1.

Why These Findings Matter for RLS

Iron deficiency is a core pathophysiological driver of secondary RLS, and anemia of any type should raise suspicion for underlying iron depletion 2, 3. The normocytic anemia in this patient warrants immediate investigation of:

• Serum ferritin (target >100 ng/mL for RLS patients, not the general population threshold)
• Transferrin saturation (target >20%)
• Serum iron and TIBC

The thrombocytopenia and elevated transaminases suggest possible chronic liver disease or bone marrow dysfunction, both of which can impair iron metabolism and storage 4.

Critical Clinical Pitfall

Do not wait for frank iron deficiency anemia to treat iron in RLS patients. Brain iron deficiency occurs independently of systemic iron stores 1. Patients with ferritin ≤100 ng/mL or transferrin saturation <20% benefit from iron supplementation even with "normal" hemoglobin 3.

Immediate Diagnostic Steps

Check iron indices specifically:

• If ferritin ≤100 ng/mL or TSAT <20%: initiate iron replacement immediately
• Consider IV ferric carboxymaltose 1000 mg (strong recommendation) over oral iron, as it bypasses GI absorption issues and directly addresses brain iron deficiency 1
• Oral ferrous sulfate 325-650 mg daily is an alternative but less effective with ferritin >50-75 ng/mL 1, 3

Associated Conditions to Evaluate

The combination of cytopenias and transaminitis requires workup for:

• Chronic liver disease (common cause of secondary RLS through iron dysregulation)
• Chronic kidney disease (RLS prevalence 24% in end-stage renal disease) 4
• Bone marrow disorders affecting iron metabolism
• Diabetes (associated with higher RLS prevalence through neuropathy) 4

Treatment Algorithm After Iron Assessment

1. First-line: Correct iron deficiency (IV ferric carboxymaltose 1000 mg preferred) 1
2. If symptoms persist after iron repletion: Initiate α2δ ligands (gabapentin 300-1800 mg, pregabalin 75-450 mg, or gabapentin enacarbil 600-1200 mg) 1, 3
3. Avoid dopamine agonists as first-line due to 7-10% annual augmentation risk 3, 5
4. For refractory cases: Low-dose opioids (methadone 5-10 mg daily) 1, 3

Important Medication Review

Stop any medications that worsen RLS:

• Serotonergic antidepressants (SSRIs, SNRIs)
• Dopamine antagonists (metoclopramide, prochlorperazine)
• Centrally acting antihistamines (diphenhydramine)

These commonly prescribed agents directly exacerbate RLS symptoms 1, 3.

Prognosis Consideration

Treating the underlying anemia alone may not resolve RLS symptoms 6. A study of anemic CHF-CRF patients showed that successful anemia correction with erythropoietin and IV iron did not improve RLS, suggesting the disorder requires specific RLS-directed iron repletion strategies and often additional pharmacotherapy 6.

The elevated transaminases and cytopenias require parallel investigation for liver disease, which itself is associated with iron dysregulation and secondary RLS 7, 8. Address both the hematologic abnormalities and RLS-specific iron targets simultaneously for optimal outcomes.